Can Bosutinib cure the disease?

Bosutinib (Bosutinib) has shown significant efficacy in the treatment of chronic myelogenous leukemia (CML), but it cannot be considered a curative treatment at present. CML is a chronic leukemia caused by mutations in the BCR-ABL fusion gene in leukemia stem cells, and the presence of the BCR-ABL gene is closely related to the abnormal proliferation and survival of leukemia cells.

The main effect of Bosutinib is to control and slow down the growth and division of leukemia cells by inhibiting the kinase activity ofBCR-ABL fusion protein. Although bosutinib can effectively inhibit the development of leukemia and improve patients' blood routine indicators in many cases, because CML is a chronic disease, patients usually require long-term or even lifelong treatment.

There is no evidence that bosutinib can completely cure CML. Even during bosutinib treatment, patients may still have detectable tiny residual leukemia cells. Therefore, bosutinib is usually regarded as a treatment that can effectively control disease progression, improve survival rate, and improve quality of life, rather than as a radical treatment.

Bosutinib is not yet available in China, so patients cannot purchase it domestically and need to purchase it through overseas channels. There are original drugs and generic drugs of bosutinib abroad. The original drugs include the Turkish original drug and the European version of the original drug. The Turkish version of the original drug costs about 2,000 to 3,000 yuan, and the European version of the original drug costs about 30,000 yuan. In addition, there are cheaper generic drugs, which cost more than one thousand yuan, and the ingredients of the original drugs and generic drugs are basically the same.